Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells

RNA Biology

Volumn 9, Issue 1, 2012, Pages 67-80

  Meyer, Cindy ^a   Eydeler, Katja ^a   Magbanua, Eileen ^a   Zivkovic, Tijana ^a   Piganeau, Nicolas ^a   Lorenzen, Inken ^b   Grötzinger, Joachim ^b   Mayer, Günter ^c   Rose John, Stefan ^b   Hahn, Ulrich ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Aptamers; Cargo delivery; Cellular uptake; Interleukin 6 receptor; RNA protein interaction; SELEX

Indexed keywords

AIR 3A; APTAMER; GLYCOPROTEIN; GLYCOPROTEIN 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OLIGONUCLEOTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; STREPTAVIDIN; UNCLASSIFIED DRUG;

ARTICLE; CELL POPULATION; CELL SURFACE; IN VITRO SELECTION; PROTEIN INTERACTION; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

EID: 84856767769     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.9.1.18062     Document Type: Article

References (55)

1. Kallen KJ, zum Buschenfelde KH, Rose-John S. The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opin Investig Drugs 1997; 6: 237-66; PMID:15989626; http://dx.doi.org/10.1517/13543784.6.3.237
2. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80:227-36; PMID:16707558; http://dx.doi.org/10.1189/ jlb.1105674
3. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994; 24:1945-8; PMID:8056053; http://dx.doi.org/10.1002/eji.1830240837
4. Müllberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23:473-80; PMID:8436181; http://dx.doi.org/10.1002/eji.1830230226
5. Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 2010; 87:396-8; PMID: 20305672; http://dx.doi.org/10.1038/clpt.2010.1
6. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249:505-10; PMID: 2200121; http://dx.doi.org/10.1126/science.2200121
7. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22; PMID:1697402; http://dx.doi.org/10. 1038/346818a0
8. Rajendran M, Ellington AD. Selection of fluorescent aptamer beacons that light up in the presence of zinc. Anal Bioanal Chem 2008; 390:1067-75; PMID:18049815; http://dx.doi.org/10.1007/s00216-007-1735-8
9. Holeman LA, Robinson SL, Szostak JW, Wilson C. Isolation and characterization of fluorophore-binding RNA aptamers. Fold Des 1998; 3:423-31; PMID: 9889155; http://dx.doi.org/10.1016/S1359-0278(98)00059-5
10. Schürer H, Stembera K, Knoll D, Mayer G, Blind M, Forster HH, et al. Aptamers that bind to the antibiotic moenomycin A. Bioorg Med Chem 2001; 9:2557-63; PMID:11557343; http://dx.doi.org/10.1016/S0968-0896(01)00030-X
11. Helmling S, Maasch C, Eulberg D, Buchner K, Schroder W, Lange C, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA 2004; 101:13174-9; PMID:15329412; http://dx.doi.org/10.1073/ pnas.0404175101
12. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009; 37:3094-109; PMID:19304999; http://dx.doi.org/10.1093/nar/gkp185
13. Gopinath SC, Sakamaki Y, Kawasaki K, Kumar PK. An efficient RNA aptamer against human influenza B virus hemagglutinin. J Biochem 2006; 139:837-46; PMID: 16751591; http://dx.doi.org/10.1093/jb/mvj095
14. Raddatz MS, Dolf A, Endl E, Knolle P, Famulok M, Mayer G. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew Chem Int Ed Engl 2008; 47:5190-3; PMID: 18512861; http://dx.doi.org/10.1002/anie.200800216
15. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008; 15:675-82; PMID:18635004; http://dx.doi.org/10.1016/j. chembiol.2008.05.016
16. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, et al. Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One 2010; 5:pii: e13050; PMID:20927342; http://dx.doi.org/10.1371/journal.pone.0013050
17. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62:4029-33; PMID:12124337
18. Chu TC, Marks JW, 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006; 66:5989-92; PMID:16778167; http://dx.doi.org/10.1158/0008-5472. CAN-05-4583
19. McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24:1005-15; PMID:16823371; http://dx.doi.org/10.1038/nbt1223
20. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2011; 108:1850-5; PMID:21233423; http://dx.doi.org/10. 1073/pnas.1011379108
21. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009; 27: 839-49; PMID:19701187; http://dx.doi.org/10.1038/nbt.1560
22. Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P, et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. J Clin Invest 2011; 121:1692-708; PMID:21519141; http://dx.doi.org/10.1172/JCI42540
23. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19:456-69; PMID:21481788; http://dx.doi.org/10.1016/j.ccr. 2011.03.009
24. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997; 15:142-5; PMID:9035138; http://dx.doi.org/10. 1038/nbt0297-142
25. Balagurumoorthy P, Brahmachari SK. Structure and stability of human telomeric sequence. J Biol Chem 1994; 269:21858-69; PMID:8063830
26. Balagurumoorthy P, Brahmachari SK, Mohanty D, Bansal M, Sasisekharan V. Hairpin and parallel quartet structures for telomeric sequences. Nucleic Acids Res 1992; 20:4061-7; PMID:1508691; http://dx.doi.org/10.1093/nar/20.15.4061
27. Halder K. Hartig JS. RNA Quadruplexes. In: Astrid Sigel, Helmut Sigel, Sigel RKO, eds. Structural and Catalytic Roles of Metal Ions in RNA. Cambridge: The Royal Society of Chemistry, 2011.
28. Mergny JL, Phan AT, Lacroix L. Following G-quartet formation by UV-spectroscopy. FEBS Lett 1998; 435:74-8; PMID:9755862; http://dx.doi.org/10. 1016/S0014-5793(98)01043-6
29. Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K, Rose-John S, Scheller J. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta 2010; 1803:234-45; PMID:20026129; http://dx.doi.org/10.1016/j.bbamcr.2009.12.001
30. Romig TS, Bell C, Drolet DW. Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr B Biomed Sci Appl 1999; 731:275-84; PMID:10510781; http://dx.doi. org/10.1016/S0378- 4347(99)00243-1
31. Kirby R, Cho EJ, Gehrke B, Bayer T, Park YS, Neikirk DP, et al. Aptamer-based sensor arrays for the detection and quantitation of proteins. Anal Chem 2004; 76: 4066-75; PMID:15253644; http://dx.doi.org/10.1021/ac049858n
32. Yan XR, Gao XW, Yao LH, Zhang ZQ. [Novel methods to detect cytokines by enzyme-linked oligonucleotide assay. ]. Sheng Wu Gong Cheng Xue Bao 2004; 20:679-82; PMID:15973989
33. Müller J, Freitag D, Mayer G, Potzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008; 6:2105-12; PMID:18826387; http://dx.doi.org/10.1111/j.1538-7836.2008.03162.x
34. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997; 4:809-16; PMID: 9384527; http://dx.doi.org/10.1016/S1074-5521(97)90114-9
35. Chen L, Li DQ, Zhong J, Wu XL, Chen Q, Peng H, et al. IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis. Osteoarthritis Cartilage 2011; 19: 711-8; PMID:21310253; http://dx.doi.org/10.1016/j.joca.2011.01.018
36. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4; PMID:16565705; http://dx.doi.org/10.1038/nature04688
37. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-8; PMID: 15538359; http://dx.doi.org/10. 1038/nature03121
38. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008; 105: 17356-61; PMID:18978032; http://dx.doi.org/10.1073/pnas.0809154105
39. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010; 4:3689-96; PMID:20550178; http://dx.doi.org/10.1021/nn901877h
40. Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, et al. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 2008; 105:15908-13; PMID:18838694; http://dx.doi.org/10.1073/pnas.0808360105
41. Meyer C, Hahn U, Rentmeister A. Cell-specific aptamers as Emerging Therapeutics. J Nucleic Acids, In press; PMID:21904667
42. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151:689-96; PMID:9284817
43. Taga T, Kawanishi Y, Hardy RR, Hirano T, Kishimoto T. Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med 1987; 166:967-81; PMID: 2821154; http://dx.doi.org/10.1084/jem.166.4.967
44. Snyers L, Fontaine V, Content J. Modulation of interleukin-6 receptors in human cells. Ann N Y Acad Sci 1989; 557:388-93, discussion 94-5; PMID:2786701; http://dx.doi.org/10.1111/j.1749-6632.1989.tb24031.x
45. Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 2010; 70:8617-29; PMID:20861190; http://dx.doi.org/10.1158/0008-5472.CAN-10-0920
46. Zohlnhöfer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, Heinrich PC. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett 1992; 306:219-22; PMID:1321736; http://dx.doi.org/10.1016/0014- 5793(92)81004-6
47. Korolenko TA, Heinrich PK, Hemmann U, Weiergraber O, Dittrich E, Graeve L. [Cell endocytosis of the complex interleukin-6-soluble interleukin-6 receptor and its intralysosomal degradation. ]. Biull Eksp Biol Med 1997; 124:527-9; PMID:9471247; http://dx.doi.org/10.1007/BF02445668
48. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem 2009; 78:857-902; PMID: 19317650; http://dx.doi.org/10.1146/annurev.biochem. 78.081307.110540
49. Thiel KW, Giangrande PH. Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 2010; 1:849-61; PMID:21643487; http://dx.doi.org/10. 4155/tde.10.61
50. van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, et al. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 1993; 268:15285-90; PMID:8325898
51. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 upregulates expression of acute-phase proteins. J Immunol 1992; 149:2021-7; PMID:1381393
52. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268:160-7; PMID:11121117; http://dx.doi.org/10.1046/j.1432-1327.2001.01867.x
53. Mayer G, Wulffen B, Huber C, Brockmann J, Flicke B, Neumann L, et al. An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro. RNA 2008; 14:524-34; PMID:18230760; http://dx.doi.org/10.1261/rna.821908
54. Bugaut A, Balasubramanian S. A sequence-independent study of the influence of short loop lengths on the stability and topology of intramolecular DNA G-quadruplexes. Biochemistry 2008; 47:689-97; PMID: 18092816; http://dx.doi.org/10.1021/bi701873c
55. Marky LA, Breslauer KJ. Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves. Biopolymers 1987; 26:1601-20; PMID: 3663875; http://dx.doi.org/10.1002/bip.360260911